As one of the largest pharmaceutical and vaccine companies, GSK has used its vast resources to create the next generation of healthcare treatments. The company's innovative new product lineup and ...
RSV vaccine sales from GSK and Pfizer have dropped significantly following revised CDC guidelines, narrowing the eligible age ...
GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of ...
In prostate cancer, Pfizer’s Talzenna already holds the broadest FDA approval within the PARP inhibitor class. | In prostate ...
UK-based pharmaceutical giant GSK, or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level ...
The latest health news includes Illumina's launch of affordable gene sequencers, Pfizer's promising cancer drug trials, CVS ...
GSK shares top the Stoxx Europe 600 index on Thursday after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands of U.S. lawsuits over claims its discontinued heartburn ...
UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over ...
GSK has always refuted claims that its discontinued heartburn drug had cancer-causing risks, arguing that expert testimonies ...
Shares of GSK rose as much as 6.5% on Thursday after the British drugmaker agreed to pay up to $2.2 billion to settle ...
The pharmaceutical giant has settled the vast majority of cases around its drug Zantac in the US, boosting investor confidence in the company.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback